Table 3. Current clinical-stage MGs

Complound	Target protein	Indication	Reference
CC-92480	IKZF1/3	MM	[75]
CC-90009	GSPT1	AML, MDS	[76]
CC-220	IKZF1/3	Relapsed/refractory MM, NHL, systemic lupus erythematosus.	[77]
E7820	RBM39	Relapsed or refractory AML, MDS or chronic myelomonocytic leukemia	[78]
CFT 7455	IKZF1/3	MM, NHL	[79]
NVP-DKY709	IKZF2	Cancer immunotherapy	[80]

MGs, molecular glues; IKZF, ikaros; MM, multiple myeloma; GSPT1, G1 to S phase transition 1; AML, acute myeloid leukemia; MDS, myeloid dysplasia syndrome; NHL, non-Hodgkin’s lymphoma.